CN101606978B - Blood-sugar reducing tea and preparation method thereof - Google Patents
Blood-sugar reducing tea and preparation method thereof Download PDFInfo
- Publication number
- CN101606978B CN101606978B CN2009101573620A CN200910157362A CN101606978B CN 101606978 B CN101606978 B CN 101606978B CN 2009101573620 A CN2009101573620 A CN 2009101573620A CN 200910157362 A CN200910157362 A CN 200910157362A CN 101606978 B CN101606978 B CN 101606978B
- Authority
- CN
- China
- Prior art keywords
- blood
- sugar
- parts
- reducing tea
- sugar reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a blood-sugar reducing tea and a preparation method thereof. The blood-sugar reducing tea is prepared by taking guava leaves, flos notoginseng, fructus momordicae and jasmine flowers as the materials through the steps of selecting the materials and removing impurities as well as rotten and deteriorated materials, then drying under 50-85 DEG C, cracking, and screening through vibrating screen; and then taking 20-60 meshes of materials, mixing, sterilizing and packaging the materials according to proportions. The blood-sugar reducing tea and the preparation method thereof have the advantages of unique composing prescription, confirmed curative effect, convenient use, economy, safety and no side effect, has the effects of clearing heat and promoting the secretion of saliva or body fluid, reducing sugar and removing fat, dispersing stagnation and dredging collaterals, and is applicable to patients with abnormal sugar tolerance and diabetics to use. Experiment research shows that the blood-sugar reducing tea and the preparation method thereof have the effects of reducing blood sugar and lightening insulin resistance, increasing insulin sensitivity, protecting Beta cell functions, and reducing serum total cholesterol and serum triglyceride without toxic side effects.
Description
One, technical field
The present invention relates to a kind of blood-sugar reducing tea and preparation method thereof.
Two, background technology
Impaired glucose tolerance (IGT) is meant patient's a kind of intermediateness of blood glucose between normal person's blood glucose value and glycosuria patient blood glucose value.It is generally accepted that at present IGT is the early stage of diabetes, is a distress phase that develops into diabetes.Along with the raising of people's living standard, the prevalence of impaired glucose tolerance obviously increases.WHO announces that in 1993 30～64 years old adult IGT prevalence in the whole world mostly is 3.0%～10.0% greatly.National Diabetes Epidemiological Investigation IGT markization prevalence was the highest by 5.78% with provincial capital in 1996, and minimum is poor counties and townships 3.14%.China has 1,300,000,000 populations now, if the IGT prevalence is calculated by average 4.46%, then number of patients will be more than 5,798 ten thousand, be higher than the number of patients (3,000 ten thousand) of China's diabetes far away.Studies show that had 1/3 IGT to change diabetes into approximately in per 5～10 years, 1/3 changes into normally, and 1/3 still keeps IGT.Develop into non-insulin-dependent diabetes mellitus (NIDDM) person every year and be about 1%～5%, the accumulation prevalence can be up to 40%.The year ratio that capital, Beijing 30～64 years old IGT of iron and steel head office transfers NIDDM to is 8.95%.This shows that though China IGT prevalence is lower than external physical data, wherein the sickness rate of diabetes is high abroad.Calculate simply that from above-mentioned data China every year, this was the problem of a significant and research by the patient who develops into diabetes among the IGT patient who makes a definite diagnosis 150～1,800,000 nearly.
Therapeutic intervention to IGT mainly is behavior intervention and pharmaceutical intervention at present, and the behavior intervention treatment comprises the adjustment life style: rational meals and increase quantity of motion.Majority thinks that the behavior intervention that IGT patient is carried out diet and exercise therapy is the effective measures that reduce the diabetes incidence rate, but still has suitable patient's state of an illness to continue progress.Though the chemical medicine of existing treatment diabetes such as sulfonylurea drugs, euglycemic agent, metformin, alpha-glucosidase inhibitor etc. can be used for treating impaired glucose tolerance, very easily cause hypoglycemia, general patient is difficult to bear.According to clinical investigation, in the impaired glucose tolerance stage, Most patients does not accept to use the chemical drugs treatment, and is ready to accept the Chinese medicine conditioning.For this reason, the present invention is guidance with the theory of Chinese medical science, on the basis of clinical experience for many years, adopting medicinal and edible Chinese medicine is the blood-sugar reducing tea of main development treatment impaired glucose tolerance, show through clinical practice, pharmaceutical composition of the present invention has no side effect the effect that has blood sugar lowering, blood fat reducing, alleviates insulin resistant to impaired glucose tolerance and slight diabetics determined curative effect.
Three, summary of the invention
The object of the present invention is to provide the blood-sugar reducing tea and preparation method thereof of the treatment impaired glucose tolerance of a kind of determined curative effect, no obvious toxic-side effects, be applicable to impaired glucose tolerance and slight diabetics.
Technical scheme of the present invention: a kind of blood-sugar reducing tea and preparation method thereof is characterized in that being prepared from by following raw material composition and weight proportion: 5～40 parts of Folium Psidii Guajavae, 1～10 part of flower of Radix Notoginseng, 0.5～8 part of Fructus Momordicae, 0.55～8 part of Flos Jasmini Sambac; Preferred weight ratio range of the present invention is: 10～25 parts of Folium Psidii Guajavae, 3～8 parts of flower of Radix Notoginseng, 1～5 part of Fructus Momordicae, 1～5 part of Flos Jasmini Sambac; Optimum weight ratio range of the present invention is: 19 parts of Folium Psidii Guajavae, 5 parts of flower of Radix Notoginseng, 3 parts of Fructus Momordicaes, 3 parts of Flos Jasmini Sambacs.
The preparation method of a kind of blood-sugar reducing tea and preparation method thereof, it is characterized in that above raw material respectively through selected, remove impurity and go rotten rotten raw material, oven dry, pulverizing, behind the reciprocating sieve sub-sieve, get 20～60 order raw materials, be mixed in proportion, sterilize, pack and form; Wherein baking temperature is at 50～85 ℃; Sterilization method is cobalt 60 radiation sterilizations, microwave sterilizating or pressure sterilizing; Every bag of specification 2～5 grams.
The invention has the advantages that the prescription uniqueness, determined curative effect, easy to use, economy, safe without toxic side effect have the dispel effect of fat, disperse blood stasis and dredge collateral of clearing away heat and promoting production of body fluid, blood sugar lowering, are applicable to impaired glucose tolerance and slight diabetics.Experimentation shows that the present invention has blood sugar lowering, alleviates insulin resistant, increases the sensitivity of insulin, and protection β cell function reduces serum total cholesterol and serum levels of triglyceride, does not see toxic and side effects.Mainly clinical, pharmacodynamics and toxicology test result of study are as follows:
Test example one: thing of the present invention is to impaired glucose tolerance patient's clinical efficacy
1, object and method: (1) diagnostic criteria (reference " Chinese treating diabetes guide " 2004): carbohydrate tolerance impaired (IGT): fasting glucose (FPG) value＜7.0mmol/L (126mg/dl), and 2 o'clock blood glucose (the 2HPG) 〉=7.8mmol/L (140mg/dl) in load back,＜11.1mmol/L (200mg/dl).(2) include the case standard in: Western medicine diagnose is the impaired glucose tolerance person, and the age is between 40～65 years old.Including case in is that blood glucose is accepted 35 routine impaired glucose tolerance patients for medical treatment altogether still abnormal ranges person after diet adds the motion intervention.Add thing of the present invention and (make every bag of 3g by Folium Psidii Guajavae, flower of Radix Notoginseng, Fructus Momordicae, Flos Jasmini Sambac for each 1 bag.), every day 3 times, 2 months is a course of treatment.(5) MAIN OUTCOME MEASURES: fasting glucose (FPG), 2 hours after the meal blood glucose (2hPG), glycolated hemoglobin (HbA
1C), plasma insulin (FINS).
2, efficacy evaluation: (1) control: 2 o'clock blood glucose in carbohydrate tolerance test clothes sugar back and fasting glucose all recover normal; (2) effective: 2 o'clock blood glucose in carbohydrate tolerance test clothes sugar back or fasting glucose reduce, but recover normal; (3) invalid: 2 o'clock blood glucose in carbohydrate tolerance test clothes sugar back and fasting glucose do not have and improve or raise.
3, clinical observation result
(1) treatment front and back two groups of FPG, 2hPG, HbA
1c, FINS comparison
FPG, 2hPG, HbA before and after table 1 treatment
1c, FINS comparison (x ± s)
Annotate: self compare P＜0.05 before and after the △ treatment.
By table 1 as seen, treat after 2 months, significant difference (p＜0.05) before and after FPG, the 2hPG treatment illustrates that thing of the present invention has the effect that reduces empty stomach and postprandial hyperglycemia preferably; Significant difference result (p＜0.05) before and after the treatment group fasting insulin horizontal stretcher shows that thing of the present invention has the effect of the insulin sensitivity of raising.
Test example two, thing of the present invention are to the influence of spontaneous type 2 diabetes mellitus KKAy mice
1, materials and methods
1.1 material
1.1.1 medicine: thing of the present invention is made by Folium Psidii Guajavae, flower of Radix Notoginseng, Fructus Momordicae, Flos Jasmini Sambac, every bag of 3g.Brewed 15 minutes with boiled water before the experiment, make every milliliter and contain the 2g crude drug.Distilled water is mixed with low, the high two kinds of concentration solution of 0.08g/ml, 0.32g/ml.4 ℃ of preservations, seven days shelf-lifves.Take out medicinal liquid before irritating the stomach prerequisite, use after being placed to room temperature.
Auspicious red (pioglitazone hydrochloride sheet) 15mg/ sheet, authentication code: the accurate word H20040631 of traditional Chinese medicines, made by Hengrui Medicine Co., Ltd., Jiangsu Prov..Take out tablet during experiment and be ground into fine powder, be mixed with the solution of desired concn 0.10mg/ml with distilled water.4 ℃ of preservations, three days shelf-lifves.Take out medicinal liquid before irritating the stomach prerequisite, use after being placed to room temperature.
1.1.2 animal: 45 of the healthy male KKAy mices of 8～12 SPF levels in age in week, 10 of the healthy male C57bl/6J mices of 8～12 SPF levels in age in week provide by Institute of Experimental Animals, Chinese Academy of Medical Sciences.
1.2 method
1.2.1 feed formula
The KKAy mice is fed full price high lipid food (available from Institute of Experimental Animals, Chinese Academy of Medical Sciences, forming: 78.8% normal feedstuff, 1% cholesterol, 10% yolk powder, 10% Adeps Sus domestica, 0.2% cholate); The C57bl/6J mice is fed the full nutrition pellet.
1.2.2 the affirmation of model
After adaptability is fed a week, the hematometry random blood sugar is got in 45 dockings of the healthy male KKAy mice of SPF level, twice random blood sugar all can be used for this test the above person of 13.9mmol/L.
1.2.3 grouping
Qualified KKAy mice amounts to 40, looks into table of random number by the random blood sugar value and is divided into 4 groups at random, 10 every group: each 10 of model group, high dose group, low dose group and positive controls (pioglitazone); Other establishes 10 of the healthy male C57bl/6J mices of SPF level and is the normal control group.
1.2.4 medication
The normal control group: gavage sterilized water by 20ml/kg/d, once a day, continuous 8 weeks.Model group: gavage sterilized water by 20ml/kg/d, once a day, continuous 8 weeks.The administration group: the high and low dose group is respectively with 1.6g/kg, and 0.4g/kg gavages and is subjected to the reagent thing, once a day, and continuous 8 weeks.Positive controls: gavage by 1.95mg/kg/d, once a day, continuous 8 weeks.
1.2.5 sample preparations
Each is organized mice and raised for 8 weeks, and the socket of the eye vein is got blood behind the fasting water 12h, leaves standstill 4 ℃ of 1500 commentaries on classics separation of serum after 2～3 hours ,-20 ℃ of preservations.
1.3 observation index and detection method
1.3.1 the growth of animal situation is observed:
Experimental session is observed animal spirit, activity, hair color, feed, drinking-water and urine quantitative changeization, and writes down body weight weekly.
1.3.2 fasting glucose concentration determination (FPG): measure fasting glucose with blood glucose meter (German Luo Kang is complete).
1.3.3 serum insulin levels is measured (Fins) on an empty stomach: radio immunoassay is measured serum insulin levels (Fins) on an empty stomach.
1.3.4 insulin action index (IAI): adopt China-Japan Friendship Hospital's Guangwei LI teaching methods, IAI=1/FPG * FINS, this value is nonnormal distribution, so get its natural logrithm during calculating.
1.3.5 four mensuration of blood fat: automatic clinical chemistry analyzer is measured four of blood fat.
1.3.6 free fatty (FFA): copper colorimetric method for determining free fatty (FFA).
(x ± s) expression uses SPSS 11.5 software analysis 1.4 the statistical method experimental data is with mean ± standard deviation.Significance relatively adopts one factor analysis of variance (oneway ANOVA) between each group.When P＜0.05, be considered to statistical significance.
2 results
2.1 ordinary circumstance
The normal control group C57bl/6J mice mental status is good, is quick on the draw, and moves freely, and fur is glossy, and body weight rises continually and steadily.Model group KKAy mice is along with the growth in age in week engenders lethargy, bradykinesia, and slow movement, fur tarnishes, and food-intake, the water yield all increase to some extent, and the urine amount increases obviously.Chinese medicine high low dose group treatment group and pioglitazone treatment group have the performance of close copy group, but degree is lighter.
2.2 thing of the present invention is to the influence of spontaneous type 2 diabetes mellitus KKAy mice fasting glucose
Respectively organize relatively (x ± s) of mice FPG, Fins, ISI level after table 2 treatment
Annotate: compare △ P＜0.01 with normal group; Compare with model group,
*P＜0.05,
*P＜0.01; Compare #P＞0.05 with the pioglitazone group.
As known from Table 2: (1) model group mice FPG raises, and compares with normal group, has significant difference (P＜0.01); Object height dosage group of the present invention and pioglitazone group are improved all obvious to FPG, compare with model group, and difference has significance (P＜0.05); Object height of the present invention, low dose group and model group compare, and difference has significance (P＜0.05); Object height dosage group of the present invention and pioglitazone group relatively do not have significant difference (P＞0.05).(2) model group mice Fins obviously raises, and compares with normal group, has significant difference (P＜0.01); Object height of the present invention, low dose group, three groups of Fins of pioglitazone group all descend, and compare with model group, and difference has significance (P＜0.01); Object height dosage group of the present invention and pioglitazone group relatively do not have significant difference (P＞0.05), and thing low dose group of the present invention and pioglitazone group relatively have significant difference (P＜0.05).(3) model group mice ISI obviously descends, and compares with normal group, has significant difference (P＜0.01); Object height of the present invention, low dose group, three groups of ISI of pioglitazone group all raise, and compare with model group, and difference has significance (P＜0.05); Object height dosage group of the present invention and pioglitazone group relatively do not have significant difference (P＞0.05).
2.3 thing of the present invention is to the influence of spontaneous type 2 diabetes mellitus KKAy mice blood lipid level
Respectively organize relatively (x ± s) of mice blood lipid level after table 3 treatment
Annotate: compare △ P＜0.05 with normal group; Compare with model group,
*P＞0.05
As known from Table 3, model group mice TC, TG, LDL-C all obviously raise, and HDL-C obviously reduces, and compare with normal group, have significant difference (P＜0.05); There are no significant (P＞0.05) than difference with model group for each group of administration, but downward trend is arranged.
2.4 thing of the present invention is to the influence of spontaneous type 2 diabetes mellitus KKAy mice FFA level
Respectively organize relatively (x ± s) of mice FFA level after table 4 treatment
Annotate: compare △ P＜0.01 with normal group; Compare with model group,
*P＜0.05,
*P＜0.01.
As known from Table 4, model group mice FFA obviously raises, and compares with normal group, has significant difference (P＜0.01); The pioglitazone group is improved obviously FFA, compares with model group, and difference has significance (P＜0.01); Object height dosage group of the present invention is compared difference with low dose group with model group have significance (P＜0.01).
It is that object of study is observed the intervention effect of thing of the present invention to the type 2 diabetes mellitus insulin resistant that spontaneous type 2 diabetes mellitus KKAy mouse model is selected in this research.The KKAy mice is a kind of hair color gene A y saltant diabetic mice, the Ay gene not only influences the hair color of mice but also can cause that the unusual syndromes of metabolism such as obesity, hyperglycemia, lipid metabolic disorder and hyperinsulinemia appear in metabolism disorder, its morbidity is to add environmental factors and bring out on the basis of inheritance susceptible, very similar to human type 2 diabetes mellitus performance, be a kind of ideal people's type diabetes animal model, be the typical model of insulin resistant.
There are some researches show that FFA raises can directly cause IR, accounts for critical role in the generation of type 2 diabetes mellitus and development.Not controlling diabetes patient's serum FFA level can be up to 1.5mmol/L.Under the normal condition, high density F FA stimulates insulin secretion, and conversely, insulin secretion inhibitory hormone sensitive lipase is active and reduce the periphery steatolysis.The type 2 diabetes mellitus patient is then because peripheral insulin resistance, the lipotropism effect of separating of insulin descended cause FFA to raise and hyperinsulinemia.A large amount of evidences show that the insulin resistant of type 2 diabetes mellitus no matter or IGT and normal pregnancy all increases relevant with FFA.Therefore, in the research to type 2 diabetes mellitus and IR, the effect of FFA in morbidity and disease progression is one of focus of research all the time at present.
This experimental result shows that model group KKAy mice produces obvious insulin resistance, shows as fasting glucose serum insulin levels, blood fat, FFA, TNF-α and obviously increases, and IAI reduces.Thing of the present invention does not have obvious influence to the every index of non-diabetic C57BL/6J mice.After thing of the present invention treated for 8 weeks, the fasting glucose of KKAy mice, all obviously improvement of serum insulin levels, insulin resistance index, FFA on an empty stomach.Blood fat has reduction trend, may be short relevant with treatment time, and its mechanism remains further to be explored.The result shows that thing of the present invention can effectively improve the depletion that the plain resistance state of spontaneous type 2 diabetes mellitus KKAy mouse islets also can delay the β cell to a certain extent, plays a protective role.Infer that its mechanism may be by acting on the receptor metasomite, the level of regulation and control free fatty and working.
Four, the specific embodiment
With specific embodiment the present invention is elaborated below:
Embodiment 1:
Take by weighing raw material according to following proportioning: 35 parts of Folium Psidii Guajavae, 8 parts of flower of Radix Notoginseng, 7 parts of Fructus Momordicaes, 7 parts of Flos Jasmini Sambacs.
Preparation method: above raw material respectively through selected, remove impurity and the rotten raw material that goes rotten, 80 ℃ of oven dry, pulverizing, behind the reciprocating sieve sub-sieve, get 30 order raw materials, be mixed in proportion, sterilize, pack and form; Wherein sterilization method is cobalt 60 radiation sterilizations, microwave sterilizating or pressure sterilizing; Every bag of specification 2～5 grams.
Embodiment 2:
Take by weighing raw material according to following proportioning: 8 parts of Folium Psidii Guajavae, 2 parts of flower of Radix Notoginseng, 1 part of Fructus Momordicae, 1 part of Flos Jasmini Sambac.
Preparation method: above raw material respectively through selected, remove impurity and the rotten raw material that goes rotten, 70 ℃ of oven dry, pulverizing, behind the reciprocating sieve sub-sieve, get 40 order raw materials, be mixed in proportion, sterilize, pack and form; Wherein sterilization method is cobalt 60 radiation sterilizations, microwave sterilizating or pressure sterilizing; Every bag of specification 2～5 grams.
Embodiment 3:
Take by weighing raw material according to following proportioning: 19 parts of Folium Psidii Guajavae, 5 parts of flower of Radix Notoginseng, 3 parts of Fructus Momordicaes, 3 parts of Flos Jasmini Sambacs.
Preparation method: above raw material respectively through selected, remove impurity and the rotten raw material that goes rotten, 70 ℃ of oven dry, pulverizing, behind the reciprocating sieve sub-sieve, get 50 order raw materials, be mixed in proportion, sterilize, pack and form; Wherein sterilization method is cobalt 60 radiation sterilizations, microwave sterilizating or pressure sterilizing; Every bag of specification 2～5 grams.
Embodiment 4:
Take by weighing raw material according to following proportioning: 19 parts of Folium Psidii Guajavae, 5 parts of flower of Radix Notoginseng, 3 parts of Fructus Momordicaes, 3 parts of Flos Jasmini Sambacs.
Preparation method: above raw material respectively through selected, remove impurity and the rotten raw material that goes rotten, 70 ℃ of oven dry, pulverizing, behind the reciprocating sieve sub-sieve, get 60 order raw materials, be mixed in proportion, sterilize, pack and form; Wherein sterilization method is cobalt 60 radiation sterilizations, microwave sterilizating or pressure sterilizing; Every bag of specification 2～5 grams.
Claims (5)
1. a blood-sugar reducing tea is characterized in that being prepared from by following raw material composition and weight proportion: 5～40 parts of Folium Psidii Guajavae, 1～10 part of flower of Radix Notoginseng, 0.5～8 part of Fructus Momordicae, 0.5～8 part of Flos Jasmini Sambac.
2. blood-sugar reducing tea as claimed in claim 1, its raw material and weight proportion are: 10～25 parts of Folium Psidii Guajavae, 3～8 parts of flower of Radix Notoginseng, 1～5 part of Fructus Momordicae, 1～5 part of Flos Jasmini Sambac.
3. blood-sugar reducing tea as claimed in claim 1, its raw material and weight proportion are: 19 parts of Folium Psidii Guajavae, 5 parts of flower of Radix Notoginseng, 3 parts of Fructus Momordicaes, 3 parts of Flos Jasmini Sambacs.
4. as each described blood-sugar reducing tea of claim 1～3, it is characterized in that: preparation method be by above raw material respectively through selected, remove impurity and the rotten raw material that goes rotten, 50～85 ℃ of oven dry, pulverizing, behind the reciprocating sieve sub-sieve, get 20～60 order raw materials, be mixed in proportion, sterilize, pack.
5. blood-sugar reducing tea as claimed in claim 4 is characterized in that: sterilization method is cobalt 60 radiation sterilizations, microwave sterilizating or pressure sterilizing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101573620A CN101606978B (en) | 2009-07-28 | 2009-07-28 | Blood-sugar reducing tea and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009101573620A CN101606978B (en) | 2009-07-28 | 2009-07-28 | Blood-sugar reducing tea and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101606978A CN101606978A (en) | 2009-12-23 |
| CN101606978B true CN101606978B (en) | 2011-04-27 |
Family
ID=41480988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009101573620A Active CN101606978B (en) | 2009-07-28 | 2009-07-28 | Blood-sugar reducing tea and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101606978B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102217686A (en) * | 2011-06-02 | 2011-10-19 | 王乃利 | Hypoglycemic tea and preparation method thereof |
| CN103271199A (en) * | 2013-06-08 | 2013-09-04 | 中山市翠山食品有限公司 | Instant psidiumguajava tea and preparation process thereof |
| CN103653148B (en) * | 2014-01-07 | 2015-01-14 | 何明 | Guava leaf liquid beverage |
| CN105494822A (en) * | 2016-02-24 | 2016-04-20 | 吴先彰 | Radix puerariae healthcare tea |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1650939A (en) * | 2004-12-03 | 2005-08-10 | 王进文 | Health care tea for preventing cancer, lowering blood fat and lowering blood pressure |
-
2009
- 2009-07-28 CN CN2009101573620A patent/CN101606978B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1650939A (en) * | 2004-12-03 | 2005-08-10 | 王进文 | Health care tea for preventing cancer, lowering blood fat and lowering blood pressure |
Non-Patent Citations (1)
| Title |
|---|
| 钟正贤等.广西40年来中草药药理研究概况.《广西中医药》.1999,第22卷(第2期),第48-49页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101606978A (en) | 2009-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102551065B (en) | Blood sugar reducing food series | |
| CN108271892A (en) | A kind of hypoglycemic health food and preparation method thereof | |
| CN101606978B (en) | Blood-sugar reducing tea and preparation method thereof | |
| CN102526479A (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN101632404A (en) | Blood sugar reducing healthy tea and preparation method thereof | |
| CN103405655A (en) | Traditional Chinese medicine composition for reducing blood glucose and preparation method thereof | |
| CN103417846A (en) | Hypoglycemic traditional Chinese medicine composition and preparation method thereof | |
| CN101716229A (en) | Health-care tea for regulating blood sugar level and preparation method thereof | |
| CN102366497B (en) | Medicinal compound preparation for treating diabetes and preparation method of medicinal compound preparation | |
| CN102861201A (en) | Medicine composition for treating diabetes and preparation method thereof | |
| CN102940800A (en) | Traditional Chinese medicine for treating diabetes | |
| CN107281386B (en) | Method for preparing medicine for treating hypertension by using dendrobium officinale and radish seeds and application | |
| CN108403818A (en) | A kind of composition of auxiliary hyperglycemic and application thereof | |
| CN101829271B (en) | Chinese medicinal compound with function of treating diabetes and preparation method and application thereof | |
| CN101406642B (en) | Antihypelipidemic compound formulation | |
| CN109223811A (en) | Panaxsaponin composition with hypoglycemic activity | |
| CN101053592B (en) | Medicinal composition for treating impaired glucose tolerance and preparation method thereof | |
| CN101879190A (en) | Composition containing curcumin and application of curcumin in preparing composition for adjusting blood sugar | |
| CN101757012A (en) | Application of hyperin in preparation of medicament for treating diabetes | |
| CN102114185B (en) | Medicament for treating insulin resistance of type 2 diabetes | |
| CN108079000A (en) | A kind of pharmaceutical composition for treating diabetes and preparation method thereof | |
| CN104922445B (en) | A kind of Traditional Chinese medicine compound composition and the preparation method and application thereof with treatment heart failure effect | |
| CN108042710A (en) | A kind of Chinese medicine composition for treating deficiency of both qi and yin and retention of damp-heat in the interior type diabetes B and its application | |
| CN1463734A (en) | A prepared Chinese medicine for treating diabetes mellitus and method for preparing same | |
| CN102430040A (en) | Medicament for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |